High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients: Gut and liver

A. Pellicelli, V. Messina, V. Giannelli, M. Distefano, V.P. Palitti, P. Vignally, P. Tarquini, A. Izzi, A. Moretti, S. Babudieri, S. Dell'Isola, M. Marignani, G. Scifo, V. Iovinella, G. Cariti, M. Pompili, F.D. Candilo, L. Fontanella, G.M. Ettorre, G. VennarecciA.M. Ippolito, G. Barbarini

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)357-367
Number of pages11
JournalLiver
Volume14
Issue number3
DOIs
Publication statusPublished - 2020

Cite this

Pellicelli, A., Messina, V., Giannelli, V., Distefano, M., Palitti, V. P., Vignally, P., Tarquini, P., Izzi, A., Moretti, A., Babudieri, S., Dell'Isola, S., Marignani, M., Scifo, G., Iovinella, V., Cariti, G., Pompili, M., Candilo, F. D., Fontanella, L., Ettorre, G. M., ... Barbarini, G. (2020). High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients: Gut and liver. Liver, 14(3), 357-367. https://doi.org/10.5009/gnl18269